PCG Capital

CytoAgents, Inc. is a clinical-stage biotechnology company based in Pittsburgh, Pennsylvania, established in 2018. The company specializes in developing innovative protein-based drugs aimed at treating viral infectious diseases, particularly focusing on life-threatening symptoms associated with Cytokine Release Syndrome (CRS). CRS is an inflammatory response characterized by an overactive immune system, often linked to conditions such as oncology CAR-T cell therapy and COVID-19. CytoAgents' lead product, GP1681, acts as an agonist of a G-protein coupled receptor and represents a novel therapeutic approach to manage the immune response in patients experiencing cytokine storms. Through its research and development efforts, CytoAgents aims to address significant unmet medical needs across various indications, enhancing treatment efficacy for patients suffering from severe systemic inflammation.